PCRX Healthcare

Pacira BioSciences, Inc.

$36.39-0.03%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 1.5B USD
Enterprise value: 1.6B USD
Full-time employees: 825

Overall health

Drawback: more debt relative to equity (0.54× vs a peer median of 0.22×)more debt vs equity (0.54× vs peers 0.22×)
About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Pacira BioSciences made a profit per share in its latest year after a loss the year before.
Sales growing faster than profits. Since 2022 (an unusually weak year for operating profit): revenue +8.9%, operating profit −68%.Since 2022: revenue +8.9%, operating profit −68%.
Since 2022, Pacira BioSciences's revenue changed +8.9% while operating profit fell 68%: costs rose faster than sales.
Share count shrinking. Shares outstanding down 13% from December 2022 to August 2026.
Pacira BioSciences had 13% fewer shares at August 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.
Cash flow well above reported profit. Free cash flow is 12.3× reported profit.
Free cash flow is 12.3× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

StockQuotient Score

59/ 100▼ 1 since Oct 27 close

Oct 5 62 → Nov 4 59 (-3)

Valuation

Is the price right?

53/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Helped by:

▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield1.0%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.32Sector median: 0.0148 · MAD: 0.0148

EBITDA yield6.7%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.68Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield12.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield46.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

76/100

Moderate▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Score 77 → 76

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a loss to a profit33% base weight · Z-score 4.46Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth3.7%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.26Sector median: 0.0584 · MAD: 0.0840

Revenue growth5.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.04Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

42/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin2.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.36Sector median: 0.0706 · MAD: 0.1217

Return on assets1.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.09Sector median: 0.0166 · MAD: 0.0537

Return on invested capital1.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.28Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin79.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity2.2%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Beta
▲ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.25

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.10Sector median: 0.6250 · MAD: 0.3380

Current ratio5.04×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.77Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.54×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.56Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Pacira BioSciences

Is Pacira BioSciences getting weaker?: Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is 59/100, down 1 since Oct 28, 2026.
How is Pacira BioSciences valued vs its peers?: Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. EBITDA yield 6.7% vs a peer median of 4.0% (stronger than 67% of peers).EBITDA yield 6.7% vs peers 4.0% (stronger than 67% of peers).
Is Pacira BioSciences growing?: Yes, faster than most of its peers. Growth scores 76/100 against 1,393 healthcare peers.
How profitable is Pacira BioSciences?: About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers. Operating margin 2.7% vs a peer median of 7.1% (weaker than 62% of peers).Operating margin 2.7% vs peers 7.1% (weaker than 62% of peers).
How risky is Pacira BioSciences?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.25 vs a peer median of 0.63 (stronger than 85% of peers).Beta 0.25 vs peers 0.63 (stronger than 85% of peers). Debt / equity 0.54× vs a peer median of 0.22× (weaker than 68% of peers).Debt / equity 0.54× vs peers 0.22× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	734.9M USD	746.2M USD	+1.5%
Net income (12 months)	5.1M USD	14.6M USD	+186.1%
Operating margin	3.3%	2.7%	−0.6 pts
Free cash flow (12 months)	132.7M USD	179.5M USD	+35.3%
Debt	367.7M USD	363.1M USD	−1.2%
Cash	144.3M USD	205.9M USD	+42.7%
Shares outstanding	39.3M	39.9M	+1.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	74.1%	70.1%	72.6%	75.7%	79.4%	▲ 3.7 pts
Operating margin	16.6%	9.0%	13.0%	-10.5%	2.6%	▲ 13 pts
Net margin	7.8%	2.4%	6.2%	-14.2%	1.0%	▲ 15 pts
Return on assets (ROA)	2.0%	0.9%	2.7%	-6.4%	0.6%	▲ 7.0 pts
Return on equity (ROE)	5.7%	2.1%	4.8%	-12.8%	1.0%	▲ 14 pts
Free cash flow margin	14.7%	17.3%	20.7%	25.5%	18.8%	▼ 6.7 pts
Current ratio	1.66×	3.37×	5.24×	2.40×	4.54×	▲ 89%
Quick ratio	1.47×	2.72×	4.17×	2.00×	3.28×	▲ 64%
Debt to equity	—	0.89×	0.60×	0.75×	0.54×	▼ 29%
Interest coverage	2.83×	1.50×	4.32×	-4.43×	1.10×	▲ 125%

PCRX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: more debt relative to equity (0.54× vs a peer median of 0.22×)more debt vs equity (0.54× vs peers 0.22×)

About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #401 of 1,157 healthcare companies (top 35%)

See how it ranks against its peers

Worth knowing

Earnings turned from a loss to a profit. Profit per share this year after a loss last year.

Pacira BioSciences made a profit per share in its latest year after a loss the year before.

Sales growing faster than profits. Since 2022 (an unusually weak year for operating profit): revenue +8.9%, operating profit −68%.Since 2022: revenue +8.9%, operating profit −68%.

Since 2022, Pacira BioSciences's revenue changed +8.9% while operating profit fell 68%: costs rose faster than sales.

Share count shrinking. Shares outstanding down 13% from December 2022 to August 2026.

Pacira BioSciences had 13% fewer shares at August 2026 than at December 2022, mainly through buybacks, so each remaining share owns a larger slice of the business.

Cash flow well above reported profit. Free cash flow is 12.3× reported profit.

Free cash flow is 12.3× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

Questions investors ask about Pacira BioSciences

Is Pacira BioSciences getting weaker?

Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is 59/100, down 1 since Oct 28, 2026.

How is Pacira BioSciences valued vs its peers?

Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. EBITDA yield 6.7% vs a peer median of 4.0% (stronger than 67% of peers).EBITDA yield 6.7% vs peers 4.0% (stronger than 67% of peers).

Is Pacira BioSciences growing?

Yes, faster than most of its peers. Growth scores 76/100 against 1,393 healthcare peers.

How profitable is Pacira BioSciences?

About as profitable as its peers. Profitability scores 42/100 against 1,393 healthcare peers. Operating margin 2.7% vs a peer median of 7.1% (weaker than 62% of peers).Operating margin 2.7% vs peers 7.1% (weaker than 62% of peers).

How risky is Pacira BioSciences?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.25 vs a peer median of 0.63 (stronger than 85% of peers).Beta 0.25 vs peers 0.63 (stronger than 85% of peers). Debt / equity 0.54× vs a peer median of 0.22× (weaker than 68% of peers).Debt / equity 0.54× vs peers 0.22× (weaker than 68% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

734.9M USD

746.2M USD

+1.5%

Net income (12 months)

5.1M USD

14.6M USD

+186.1%

Operating margin

3.3%

2.7%

−0.6 pts

Free cash flow (12 months)

132.7M USD

179.5M USD

+35.3%

Debt

367.7M USD

363.1M USD

−1.2%

Cash

144.3M USD

205.9M USD

+42.7%

Shares outstanding

39.3M

39.9M

+1.3%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

74.1%

70.1%

72.6%

75.7%

79.4%

▲ 3.7 pts

Operating margin

16.6%

9.0%

13.0%

-10.5%

2.6%

▲ 13 pts

Net margin

7.8%

2.4%

6.2%

-14.2%

1.0%

▲ 15 pts

Return on assets (ROA)

2.0%

0.9%

2.7%

-6.4%

0.6%

▲ 7.0 pts

Return on equity (ROE)

5.7%

2.1%

4.8%

-12.8%

1.0%

▲ 14 pts

Free cash flow margin

14.7%

17.3%

20.7%

25.5%

18.8%

▼ 6.7 pts

Current ratio

1.66×

3.37×

5.24×

2.40×

4.54×

▲ 89%

Quick ratio

1.47×

2.72×

4.17×

2.00×

3.28×

▲ 64%

Debt to equity

—

0.89×

0.60×

0.75×

0.54×

▼ 29%

Interest coverage

2.83×

1.50×

4.32×

-4.43×

1.10×

▲ 125%